1. Home
  2. ECPG vs PHAT Comparison

ECPG vs PHAT Comparison

Compare ECPG & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ECPG
  • PHAT
  • Stock Information
  • Founded
  • ECPG 1998
  • PHAT 2018
  • Country
  • ECPG United States
  • PHAT United States
  • Employees
  • ECPG N/A
  • PHAT N/A
  • Industry
  • ECPG Finance Companies
  • PHAT Biotechnology: Pharmaceutical Preparations
  • Sector
  • ECPG Finance
  • PHAT Health Care
  • Exchange
  • ECPG Nasdaq
  • PHAT Nasdaq
  • Market Cap
  • ECPG 905.2M
  • PHAT 820.8M
  • IPO Year
  • ECPG 1999
  • PHAT 2019
  • Fundamental
  • Price
  • ECPG $44.65
  • PHAT $11.00
  • Analyst Decision
  • ECPG Strong Buy
  • PHAT Strong Buy
  • Analyst Count
  • ECPG 3
  • PHAT 5
  • Target Price
  • ECPG $62.67
  • PHAT $16.40
  • AVG Volume (30 Days)
  • ECPG 308.9K
  • PHAT 1.0M
  • Earning Date
  • ECPG 11-05-2025
  • PHAT 11-06-2025
  • Dividend Yield
  • ECPG N/A
  • PHAT N/A
  • EPS Growth
  • ECPG N/A
  • PHAT N/A
  • EPS
  • ECPG N/A
  • PHAT N/A
  • Revenue
  • ECPG $1,467,587,000.00
  • PHAT $114,039,000.00
  • Revenue This Year
  • ECPG $27.55
  • PHAT $207.52
  • Revenue Next Year
  • ECPG $5.84
  • PHAT $96.46
  • P/E Ratio
  • ECPG N/A
  • PHAT N/A
  • Revenue Growth
  • ECPG 15.50
  • PHAT 1049.82
  • 52 Week Low
  • ECPG $26.45
  • PHAT $2.21
  • 52 Week High
  • ECPG $51.77
  • PHAT $19.71
  • Technical
  • Relative Strength Index (RSI)
  • ECPG 64.26
  • PHAT 46.33
  • Support Level
  • ECPG $43.02
  • PHAT $10.84
  • Resistance Level
  • ECPG $45.29
  • PHAT $13.00
  • Average True Range (ATR)
  • ECPG 1.20
  • PHAT 0.67
  • MACD
  • ECPG 0.10
  • PHAT -0.25
  • Stochastic Oscillator
  • ECPG 69.52
  • PHAT 7.41

About ECPG Encore Capital Group Inc

Encore Capital Group Inc is an international specialty finance company. It provides debt recovery solutions for consumers and property owners across a broad range of financial assets. The company purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals as the consumers repay their obligations and work toward financial recovery. Encore has only a reportable segment portfolio purchasing and recovery.

About PHAT Phathom Pharmaceuticals Inc.

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Share on Social Networks: